Sepsis Diagnosis

Sepsis is a worldwide problem that can cause devastating patient consequences and incur significant healthcare costs. But diagnosing sepsis is challenging. Delays in diagnosing sepsis and initiating treatment result in increased symptom severity and patient risk, higher rates of long-term complications and mortality, and greater costs to healthcare systems.

Early sepsis detection improves patient prognosis and reduces the cost of sepsis-related care. Beckman Coulter is currently the only company providing all IVD testing modalities for sepsis diagnosis and management.1

White Paper Early Sepsis Detection: Reducing Mortality Rates and Hospital Costs2

Sepsis is a global problem in developed and resource-poor countries alike, and it is increasing at an annual rate of 1.5%, meaning that it is now killing more individuals than prostate cancer, breast cancer and HIV/AIDS combined3. Read more about how together, we can detect sepsis earlier; resulting in better patient prognosis and reduced cost.4

Download white paper

Video Strengthen Clinical Decision-Making

The Early Sepsis Indicator uses the DxH series hematology analyzer's enhanced Coulter technology, which offers near native-state cellular characterization. The analyzer's powerful VCS 360 technology can uniquely detect morphological changes in monocytes, cells that play a role in the dysregulated immune response to sepsis. Identifying these monocyte morphological changes provides insight into possible sepsis earlier than other indicators.

Watch video
References:

1Sepsis related portfolio is comparison for major IVD companies January 2019

///Table to be entered here

 

2For more information, download the Instructions for Use for the product

3

4

  • Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive care medicine 2017;43:304-77
  • Jones SL et al. "Reductions in Sepsis Mortality and Costs After Design and Implementation of a Nurse-based Early Recognition and Response Program." Jt Comm J Qual Patient Saf, vol. 41, no. 11. 2015, pp. 483–91.
  • Judd WR, Stephens DM, Kennedy DA. "Clinical and Economic Impact of a Quality Improvement Initiative to Enhance Early Recognition and Treatment of Sepsis." Ann Pharmacol, vol. 48, no. 10. 2014, pp. 1269–75.